LATEST PSYCHEDELICS STOCKS NEWS

Allied Corp Announces Approval of Research and Plant Breeding License for Psychoactive and Non-Psychoactive Cannabis in Colombia

KELOWNA, British Columbia, Sept. 30, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that is has been granted additional licensing that enables the Company to function as a research and plant breeding unit for psychoactive and non-psychoactive Cannabis in Colombia. The activities that are included in ... Read More...

Delic Partnership with Paradigm Healthcare of Georgia Brings Clinically Relevant Toxicology Testing to Ketamine Treatment for First Time

Psychedelic Treatment Chain Ketamine Infusion Centers Will Leverage State-of-the-Art Toxicology Testing Solution to Ensure Highest Quality Results Across Locations VANCOUVER, BC, Sept. 30, 2021 - Delic Holding Corp Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness pl... Read More...

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

TORONTO, Sept. 29, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor. Dr. Laughren will advise on regulatory matters as it pertains to KETABET™, ... Read More...

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint /NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, Sept. 29, 2021 - Delic Holdings Corp. ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously anno... Read More...

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

TORONTO, Sept. 28, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to announce that it has closed its previously announced private placement with institutional investors of its common shares (“Common Shares”) and warrants to purchase comm... Read More...

Pure Extracts and Psyence Group Form Joint Venture for Psychedelic Medicinal Mushroom Extracts

VANCOUVER, British Columbia, Sept. 28, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”) and Psyence Group Inc. (CSE: PSYG) (“Psyence”) are pleased to announce the incorporation of a joint venture company, Pure Psyence Corp. (“Pure Psyence” or the “JV”), for the development... Read More...

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD VANCOUVER, BC, Sept. 28, 2021 - Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical rese... Read More...

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Ex... Read More...

Lamar Odom and His Life-Saving Journey with Psychedelics

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwo... Read More...

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

First-of-its-kind study targets a female sexual disorder affecting an estimated 9.5 million women in the U.S. alone VANCOUVER, BC, Sept. 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, introduces its "Desire Project," a clinical ... Read More...

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

TORONTO, Sept. 24, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in ... Read More...

Novamind Announces DTC Eligibility for its Common Shares

TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the U.S.The DT... Read More...

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has entered into a securities purchase agreement with institutional investors... Read More...

Allied Corp Provides Results of Recent Third Party Audit Confirming Production Costs and Optimization of Production

KELOWNA, British Columbia, Sept. 24, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the results of a third party audit that was conducted at the Allied Colombian Campus. The focus of the audit was Allied’s cost of production, inventory control and optimization of its production approach. On September... Read More...

Microdose Psychedelic Insights Announces Entheon Biomedical, Levitee Labs, and Women in Psychedelics to take centre stage at Psychedelic Capital: September 30, 2021

Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: September 2021 conference to be taking place on September 30, 2021, starting at 1:30pm EDT. The September edition will engage in discussions on Novel Psychedelic Molecules and Women in Psychedelic... Read More...

Delic Announces C$7.0 Million Private Placement With Institutional Investor

/NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, Sept. 23, 2021 - Delic Holdings Corp. ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approxima... Read More...

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform VANCOUVER, BC, Sept. 23, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licen... Read More...

Bright Minds Biosciences Provides Scientific Update

Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022VANCOUVER, British Columbia, Sept. 22, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment o... Read More...

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

TORONTO, Sept. 21, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares® Investments LLC (“AdvisorShares”), a leading sponsor... Read More...

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage National Presence Will Bring Psychedelic Wellness Treatment to the Masses VANCOUVER, BC, Sept. 20, 2021 - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (... Read More...

Allied Corp. Announces Approval of Second CBD Isolate Import Permit for Australia and Submits Application for the Import of Dried Cannabis

KELOWNA, British Columbia., Sept. 20, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has received approval of a second import permit for export of CBD isolate produced at Allied’s Colombian campus that is destined for the Australian market. In addition to this, through its Australian partner,... Read More...

MINDCURE to Participate in Maxim Group LLC’s Advances in Mental Health Virtual Conference

VANCOUVER, BC, Sept. 17 , 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conferenc... Read More...

Pure Extracts Ships Initial Order of Edible Gummies to Alberta

VANCOUVER, British Columbia, Sept. 16, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, P... Read More...

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, Sept. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of d... Read More...

Allied Corp Provides Update Regarding Nevada Building and Option to Purchase Nevada State License

KELOWNA, British Columbia, Sept. 15, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has completed the construction of its 8900 square foot modular building that is currently situated in the City of North Las Vegas. In addition to this, the City of North Las Vegas has now approved the land use... Read More...

Aion Therapeutic Provides Default Status Update

TORONTO, Sept. 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). On August 31, 2021, the Company anno... Read More...

Red Light Holland Engages Marketing Veteran and Brand Strategist, Ridley Doolittle, as Advisor to Advisory Board

Toronto, Ontario--(Newsfile Corp. - September 14, 2021) - Red Light Holland Corp. (CSE: TRIP) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles is pleased to announce that it has engaged Ridley Doolittle, to serve as an advisor ("Advisor") t... Read More...

Red Light Holland Expands iMicrodose Branded Product Offerings and Launches the Sale of All-in-One Mushroom Fruiting Extracts; Capsules and Tinctures

Toronto, Ontario--(Newsfile Corp. - September 13, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have expanded their iMicrodose product... Read More...

Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process

KELOWNA, British Columbia, Sept. 10, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has initiated the manufacturing activities for Psilonex™ RX – Allied’s proprietary psilocybin product. On June 29, 2021, Allied announced its manufacturing agreement with HAVN Life Sciences to manufacture Psil... Read More...

The World’s Premiere Psychedelic and Wellness Event/

Meet Delic, the revolutionary, two-day immersive edutainment experience for the world's leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021 VANCOUVER, BC, Sept. 9, 2021 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedel... Read More...

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

VANCOUVER, British Columbia, Sept. 09, 2021 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 “The ... Read More...

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics TORONTO, Sept. 09, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, ... Read More...